AVS Bio Acquires ImmunoPrecise Antibodies Europe, Expanding Antibody Discovery and Protein Production Capabilities

Reuters

08/06

AVS Bio Acquires ImmunoPrecise Antibodies Europe, Expanding Antibody Discovery and Protein Production Capabilities

Arlington Capital Partners' portfolio company, AVS Bio, has expanded its capabilities in antibody discovery and protein production through the acquisition of ImmunoPrecise Antibodies Europe from ImmunoPrecise Antibodies Ltd. This strategic move enhances AVS Bio's European presence, adding advanced services in antibody discovery, protein expression, and organoid growth factor development to its portfolio. With facilities in Utrecht and Oss, Netherlands, ImmunoPrecise Antibodies Europe provides comprehensive services to biotechnology and pharmaceutical companies, supporting the development of next-generation biologics. Post-acquisition, the company will continue to operate under its current management as a key European hub within the AVS Bio network, serving global pharmaceutical markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806420153) on August 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557764371"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557764371\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557764371?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557764371","market":"us","top_or_hot":-1,"title":"AVS Bio Acquires ImmunoPrecise Antibodies Europe, Expanding Antibody Discovery and Protein Production Capabilities","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AVS Bio Acquires ImmunoPrecise Antibodies Europe, Expanding Antibody Discovery and Protein Production Capabilities\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arlington Capital Partners' portfolio company, AVS Bio, has expanded its capabilities in antibody discovery and protein production through the acquisition of ImmunoPrecise Antibodies Europe from ImmunoPrecise Antibodies Ltd. This strategic move enhances AVS Bio's European presence, adding advanced services in antibody discovery, protein expression, and organoid growth factor development to its portfolio. With facilities in Utrecht and Oss, Netherlands, ImmunoPrecise Antibodies Europe provides comprehensive services to biotechnology and pharmaceutical companies, supporting the development of next-generation biologics. Post-acquisition, the company will continue to operate under its current management as a key European hub within the AVS Bio network, serving global pharmaceutical markets.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806420153) on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AVS Bio Acquires ImmunoPrecise Antibodies Europe, Expanding Antibody Discovery and Protein Production Capabilities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAVS Bio Acquires ImmunoPrecise Antibodies Europe, Expanding Antibody Discovery and Protein Production Capabilities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-06 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AVS Bio Acquires ImmunoPrecise Antibodies Europe, Expanding Antibody Discovery and Protein Production Capabilities\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arlington Capital Partners' portfolio company, AVS Bio, has expanded its capabilities in antibody discovery and protein production through the acquisition of ImmunoPrecise Antibodies Europe from ImmunoPrecise Antibodies Ltd. This strategic move enhances AVS Bio's European presence, adding advanced services in antibody discovery, protein expression, and organoid growth factor development to its portfolio. With facilities in Utrecht and Oss, Netherlands, ImmunoPrecise Antibodies Europe provides comprehensive services to biotechnology and pharmaceutical companies, supporting the development of next-generation biologics. Post-acquisition, the company will continue to operate under its current management as a key European hub within the AVS Bio network, serving global pharmaceutical markets.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806420153) on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPA","symbol_name":"Immunoprecise Antibodies Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL7Xxl1K:1","article_id":"2557764371","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557764371","pubTimestamp":1754481658,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arlington Capital Partners' portfolio company, AVS Bio, has expanded its capabilities in antibody discovery and protein production through the acquisition of ImmunoPrecise Antibodies Europe from ImmunoPrecise Antibodies Ltd. This strategic move enhances AVS Bio's European presence, adding advanced services in antibody discovery, protein expression, and organoid growth factor development to its portfolio. With facilities in Utrecht and Oss, Netherlands, ImmunoPrecise Antibodies Europe provides comprehensive services to biotechnology and pharmaceutical companies, supporting the development of next-generation biologics. Post-acquisition, the company will continue to operate under its current management as a key European hub within the AVS Bio network, serving global pharmaceutical markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPA":"Immunoprecise Antibodies Ltd","BK4121":"生命科学工具和服务"},"translate_title":"AVS Bio收购ImmunoPrecise Antibodies Europe，扩大抗体发现和蛋白质生产能力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"AVS Bio Acquires ImmunoPrecise Antibodies Europe, Expanding Antibody Discovery and Protein Production Capabilities\n    \n\n        Arlington Capital Partners' portfolio company, AVS Bio, has expanded its capabilities in antibody discovery and protein production through the acquisition of ImmunoPrecise Antibodies Europe from ImmunoPrecise Antibodies Ltd. This strategic move enhances AVS Bio's European presence, adding advanced services in antibody discovery, protein expression, and organoid growth factor development to its portfolio. With facilities in Utrecht and Oss, Netherlands, ImmunoPrecise Antibodies Europe provides comprehensive services to biotechnology and pharmaceutical companies, supporting the development of next-generation biologics. Post-acquisition, the company will continue to operate under its current management as a key European hub within the AVS Bio network, serving global pharmaceutical markets.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806420153) on August 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}